n their realm of expertise at the cellular and molecular level in order to develop enhancements to current products and conduct applied research to introduce new products. In addition, the company has formed alliances with several organizations in other countries (including Japan's Kirin) in order to augment its market presence (Rundle & Moore, 1995, p. 3).
Amgen's primary diversity issue stems from its core business strategy, which is to bring together marketing and technical personnel from the beginning of the product development cycle. This requires that individuals with diverse backgrounds and areas of expertise be able to work together. Adding to the difficulty is Amgen's narrow product focus: if a new product does not fit within Amgen's strict parameters, it is not pursued. These parameters include ailments which cause extreme suffering and which can be cured or treated with drugs developed through biotechnology (Gertz, 1995, p. 21).
Recognizing that Amgen also needs a physical pr
...